Medicine Information

New Antidepressant Developments and Approvals


New antidepressant development, until fairly recently, was at best a random, and at worst a problematic and frustrating, process. Often, medications that were developed for one thing were discovered quite accidentally to have much more important therapeutic effects for a completely different disorder. It has been well described that some of the original antipsychotics were originally developed to assist in anesthesia, and some of the original new antidepressants were originally intended to be medications for tuberculosis or psychosis. New antidepressant development was done on a "chemical" basis; that is, guesses were made as to compounds that would be safe and effective based on chemical structures of established medications. This was very much a trial-and-error process, since very little was known about how these drugs worked and very little could be measured beyond actually giving them to a patient.

New antidepressant development always has been and always will be a partnership between efficacy (ie, whether the drug is effective) and safety (ie, whether the drug can be tolerated by a patient). There were very few ways of knowing the answers to those two questions about any given compound unless you tried it, a process not without its obvious risks. It should be noted that vagus nerve stimulation for depression clearly meets the two main FDA requirements of safety and efficacy.

Medications to treat depression; mild, severe, bipolar, or treatment-resistant, make the news most frequently, and deservedly so. Their progress and approval can potentially benefit almost 8 million Americans who suffer from some form of depression. Because there seems to be more frequency now of depression that is treatment-resistant, meaning most methods of treatment (medications, psychotherapy, electroconvulsive therapy, or a combination of more than one treatment) have failed for a patient, the approval of new antidepressants from companies like Merck, Lilly, and Pfizer, are more important than ever. This is because a new class of medication for treating depression has not been developed in over a decade.

On July 18th, 2005 the FDA approved the first ever treatment long term treatment option for depression; vagus nerve stimulation. You can learn more about this remarkable treatment at http://www.VagusNerveStimulator.com There is a free electronic newsletter to keep you up-to-date.

Charles Donovan was a patient in the FDA investigational trial of vagus nerve stimulation as a treatment for chronic or recurrent treatment-resistant depression. He was implanted with the vagus nerve stimulator in April of 2001. He chronicles his journey from the grips of depression thanks to vagus nerve stimulation therapy in his book:

Out of the Black Hole: The Patient's Guide to Vagus Nerve Stimulation and Depression

The book was exhibited at the American Psychiatric Association's Annual Meeting in May. It is available on his web site and 24 hours a day/7 days a week through the toll free number 1-888-VAGUS-88. If you use discount code FDAYES(all caps), it will save you 25% off the cost of the book and you will get automatic free shipping via U.S. Postal Priority Mail.

The book is also available through Amazon.com and Barnes & Noble.com. The discount does not apply at these two sites.

He is the founder of the http://www.VagusNerveStimulator.com Web Site


MORE RESOURCES:
This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news


New York Post

Venezuelans with transplants live in fear as medicine runs out
New York Post
After years leading normal lives, they now live in fear as Venezuela's economic collapse under President Nicolas Maduro has left the once-prosperous OPEC nation unable to purchase sufficient foreign medicine or produce enough of its own. Some 31 ...
PETRO's backing (from Whitepaper) - El PetroEl Petro
Venezuela: 82.4M Units of Petro Cryptocurrency AvailableteleSUR English

all 177 news articles »


#MeToo in medicine: Women, harassed in hospitals and operating ...
NBCNews.com
In a months-long investigation, NBC News spoke with nearly a dozen women and experts who described widespread misconduct in hospitals and health care.

and more »


OncLive

Gastrointestinal Cancers Entering Age of Precision Medicine
OncLive
He: We had 4 excellent faculty who talked about the updates to pancreatic and hepatobiliary cancer treatment, treatment of neuroendocrine tumors (NETs) of the GI tract, and precision medicine. Molecular profiling has been identified as a very important ...



The Courier-Journal

University of Louisville takes its medicine and starts healing process | Tim Sullivan
The Courier-Journal
There's never a wrong time to do the right thing. There's rarely a point where a public institution is better served by technicalities than truth. The University of Louisville has paid a high price for coming clean with its dirty laundry, with self ...

and more »


MyNorthwest.com

Ayurveda: a 5000 year old tradition of eating where food is medicine
MyNorthwest.com
Singer songwriter Nicki Bluhm is the latest guest on my podcast, Your Last Meal. For her last meal she wants a classic steakhouse dinner, complete with scalloped potatoes and creamed spinach. But in her daily life, she follows an Ayurvedic diet; a 5 ...



גלובס

Globes English - Vaica reminds patients to take medicine - גלובס
גלובס
The Israeli company adapts its reminders to the patient's age and the type of medicine.

and more »


VentureBeat

4 ways AI could help shape the future of medicine
VentureBeat
At times, progress occurs so quickly that it's difficult to separate science fiction from real life. Just five decades ago, computers were massive, unwieldy machines running on punch cards and primitive circuits. Today, a single smartphone has more ...



PR Newswire (press release)

Personalized Lifestyle Medicine Institute to Host 2018 Thought Leaders Consortium in Tucson
PR Newswire (press release)
SEATTLE, Feb. 20, 2018 /PRNewswire/ -- The Personalized Lifestyle Medicine Institute (PLMI) will host the Sixth Annual Thought Leaders Consortium Oct. 12-13, 2018 at the Westin La Paloma Resort and Spa in Tucson, Arizona. The title of the 2018 ...

and more »


Equities Focus

Loxo Oncology Will Fulfill The Promise Of Precision Medicine
Seeking Alpha
Based in Stamford, Connecticut, Loxo Oncology is dedicated to developing precision medicines against genetically defined cancers. Its highly selective drugs in the pipeline will shift the paradigm of cancer treatment from the traditional "one-size-fits ...
Financial Newsletter - ZacksZacks
Loxo Oncology, Inc. - LOXO - Stock Price Today - ZacksZacks

all 39 news articles »


Huntington Herald Dispatch

UCD School of Medicine scores high in NIH research funding
Davis Enterprise
For the first time, UC Davis School of Medicine has ranked in the top 20 percent of institutions in the country for research funding from the National Institutes of Health. “The proportion of NIH funding is an important measure of research excellence ...
National Institutes of Health guests visit School of MedicineHNN Huntingtonnews.net

all 3 news articles »

Google News

home | site map | Dr. Thad Thomas
© 2006